Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 7711 results

  1. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years TS ID 12116

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509

    Awaiting development [GID-TA11658] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510

    Awaiting development [GID-TA11635] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development [GID-DG10083] Expected publication date: 17 July 2025

    Diagnostics guidance
    In development

  6. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    Awaiting development [GID-TA11643] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]

    Awaiting development [GID-TA11638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    Diagnostics guidance
    Published
    31 July 2024
    View recommendations

    Sections for DG59

  11. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

    In development [GID-TA11106] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development